Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;81(6):1362-9.
doi: 10.1016/j.gie.2014.12.029. Epub 2015 Mar 24.

Recurrent intestinal metaplasia after radiofrequency ablation for Barrett's esophagus: endoscopic findings and anatomic location

Cary C Cotton  1 , W Asher Wolf  1 , Sarina Pasricha  1 , Nan Li  1 , Ryan D Madanick  1 , Melissa B Spacek  1 , Kathleen Ferrell  1 , Evan S Dellon  1 , Nicholas J Shaheen  1
Affiliations

Recurrent intestinal metaplasia after radiofrequency ablation for Barrett's esophagus: endoscopic findings and anatomic location

Cary C Cotton et al. Gastrointest Endosc. 2015.

Abstract

Background: Radiofrequency ablation (RFA) is a safe and effective treatment for Barrett's esophagus (BE) that results in high rates of complete eradication of intestinal metaplasia (CEIM). However, recurrence is common after CEIM, and surveillance endoscopy is recommended. Neither the anatomic location nor the endoscopic appearance of these recurrences is well-described.

Objective: Describe the location of histologic specimens positive for recurrence after CEIM and the testing performance of endoscopic findings for the histopathologic detection of recurrence.

Design: Retrospective cohort.

Setting: Single referral center.

Patients: A total of 198 patients with BE with at least 2 surveillance endoscopies after CEIM.

Interventions: RFA, EMR, surveillance endoscopy.

Main outcome measurements: The anatomic location and histologic grade of recurrence.

Results: In a mean 3.0 years of follow-up, 32 (16.2%; 95% confidence interval [CI], 11.0%-22.0%) patients had recurrence of disease, 5 (2.5%; 95% CI, 0.3%-4.7%) of whom progressed beyond their worst before-treatment histology. Recurrence was most common at or near the gastroesophageal junction (GEJ). Recurrence>1 cm proximal to the GEJ always was accompanied by endoscopic findings, and random biopsies in these areas detected no additional cases. The sensitivity of any esophageal sign under high-definition white light or narrow-band imaging for recurrence was 59.4% (42.4%, 76.4%), and the specificity was 80.6% (77.2%, 84.0%).

Limitations: Single-center study.

Conclusion: Recurrent intestinal metaplasia often is not visible to the endoscopist and is most common near the GEJ. Random biopsies>1 cm above the GEJ had no yield for recurrence. In addition to biopsy of prior EMR sites and of suspicious lesions, random biopsies oversampling the GEJ are recommended.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 1a and 1b Distribution of recurrences by proximal distance from the top of gastric folds in terms of (a) absolute distance and (b) distance as a proportion of initial Barrett’s esophagus segment length. BE, Barrett’s esophagus; TGF, top of gastric folds; IM, intestinal metaplasia; LGD, low grade dysplasia; HGD, high grade dysplasia; IMC, intramucosal adenocarcinoma; EAC, invasive esophageal adenocarcinoma; TIM, top of intestinal metaplasia.
Figure 1
Figure 1
Figure 1a and 1b Distribution of recurrences by proximal distance from the top of gastric folds in terms of (a) absolute distance and (b) distance as a proportion of initial Barrett’s esophagus segment length. BE, Barrett’s esophagus; TGF, top of gastric folds; IM, intestinal metaplasia; LGD, low grade dysplasia; HGD, high grade dysplasia; IMC, intramucosal adenocarcinoma; EAC, invasive esophageal adenocarcinoma; TIM, top of intestinal metaplasia.
Figure 2
Figure 2
Histologic grade of recurrence by distance from TGF. TGF, top of gastric folds; IM, intestinal metaplasia; LGD, low grade dysplasia; HGD, high grade dysplasia; IMC, intramucosal adenocarcinoma; EAC, esophageal adenocarcinoma.
Figure 3
Figure 3
Visibility of endoscopic signs of recurrent intestinal metaplasia under plain white light and narrow band imaging by histologic grade of recurrence. IM, intestinal metaplasia; LGD, low grade dysplasia; HGD, high grade dysplasia; IMC, intramucosal adenocarcinoma; EAC, invasive esophageal adenocarcinoma.
See this image and copyright information in PMC

References

    1. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360:2277–88. - PubMed
    1. Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett’s Esophagus: systematic review and meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2013;11:1245–55. - PMC - PubMed
    1. Gorospe EC, Wang KK. Barrett oesophagus in 2013: risk stratification and surveillance in Barrett oesophagus. Nature reviews Gastroenterology & hepatology. 2014;11:82–4. - PMC - PubMed
    1. Bedi AO, Kwon RS, Rubenstein JH, et al. A survey of expert follow-up practices after successful endoscopic eradication therapy for Barrett’s esophagus with high-grade dysplasia and intramucosal adenocarcinoma. Gastrointestinal endoscopy. 2013;78:696–701. - PMC - PubMed
    1. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009;136:2101–14. e1–6. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources